COMPANY

Radiomedix, Inc.

HQ: Houston, TX source · radiomedix.com ↗ · Southwest

Also known as RadioMedix · 1 open job · last seen Oct 23, 2026 · 7 sources

Profile checked Oct 10, 2026

Keywords: Neuroendocrine Tumors Glioblastoma Multiforme Pancreatic Ductal Adenocarcinoma metastatic melanoma 64Cu-DOTATATE

1Open jobs 2Trials (company is sponsor)5NIH grants

Hiring

Title	Location (from posting)	Employer posted	First seen
Radiochemist	Houston, TX	Not stated	Oct 11, 2026

See all 1 job

Timeline

Aug 15, 2026 Trial start Phase 1: Study of 203Pb-RMX-VH-PIB Dosimetry and Biodistribution in Patients With Glioblastoma Multiform (GBM) and Pancreatic Ductal Adenocarcinoma (PDAC) source ↗
Aug 23, 2018 Trial start Phase 3: Imaging of Patients With Known or Suspected Somatostatin Receptor Positive Neuroendocrine Tumors Using Cu64-DOTATATE source ↗

Upcoming milestones

Dec 31, 2026 (ESTIMATED) · Phase 1 · Study of 203Pb-RMX-VH-PIB Dosimetry and Biodistribution in Patients With Glioblastoma Multiform (GBM) and Pancreatic Ductal Adenocarcinoma (PDAC) · NCT07733674

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 2

Record	Title	Phase	Status	Start	Primary completion
NCT07733674	Study of 203Pb-RMX-VH-PIB Dosimetry and Biodistribution in Patients With Glioblastoma Multiform (GBM) and Pancreatic Ductal Adenocarcinoma (PDAC)	Phase 1	Recruiting	Aug 15, 2026	Dec 31, 2026 (estimated)
NCT03673943	Imaging of Patients With Known or Suspected Somatostatin Receptor Positive Neuroendocrine Tumors Using Cu64-DOTATATE	Phase 3	Completed	Aug 23, 2018	Mar 23, 2019 (actual)

NIH awards 5

Annual award amounts. Total $4.4M.

Aug 5, 2022 NIH award 5R44CA265421-02 FY2022: $1,451,761 awarded for that fiscal year; activity R44 (SBIR); PI TWOROWSKA, IZABELA; recipient as written: RADIOMEDIX, INC., HOUSTON, TX. Targeted alpha-emitter therapy of patients w source ↗
Sep 7, 2021 NIH award 1R44CA265421-01 FY2021: $548,182 awarded for that fiscal year; activity R44 (SBIR); PI TWOROWSKA, IZABELA; recipient as written: RADIOMEDIX, INC., HOUSTON, TX. Targeted alpha-emitter therapy of patients wit source ↗
2018 NIH contract (government contract; not a grant and not an investment round) 261201800048C-0-0-1 FY2018: $1,994,002 awarded for that fiscal year; activity N01 (OTHER_NIH); PI TWOROWSKA, IZABELA; recipient as written: RADIOMEDIX, INC., HOUSTON, TX. IGF::OT::IGFN source ↗
2016 NIH contract (government contract; not a grant and not an investment round) 261201600015C-0-0-1 FY2016: $298,132 awarded for that fiscal year; activity N43 (OTHER_NIH); PI TWOROWSKA, IZABELA; recipient as written: RADIOMEDIX, INC., HOUSTON, TX. IGF::OT::IGF TA source ↗
Jul 25, 2014 NIH award 1R43CA186364-01 FY2014: $149,936 awarded for that fiscal year; activity R43 (SBIR); PI TWOROWSKA, IZABELA; recipient as written: RADIOMEDIX, INC., HOUSTON, TX. Targeted Theranostics for Metastatic Melanoma source ↗

Open jobs 1

Title	Location (from posting, not HQ)	Employer posted	First seen	Level
Radiochemist	Houston, TX	Not stated	Oct 11, 2026	Mid

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.